logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Places Idenix Pharma's IDX19368 On Clinical Hold

Idenix Pharmaceuticals Inc. (IDIX) announced that it received verbal notice from the U.S. Food and Drug Administration or FDA that a clinical hold has been placed on IDX19368, the Company's next-generation nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus or HCV infection.

Idenix said that the news follows an announcement that it made on August 16, 2012 related to a partial clinical hold placed on IDX184, the company's lead nucleotide polymerase inhibitor also under development for the treatment of HCV.

The FDA verbally informed Idenix that it placed IDX19368 on clinical hold due to concerns related to the serious cardiac-related adverse events reported for HCV patients treated with BMS-986094, a nucleotide polymerase inhibitor previously under development by Bristol-Myers Squibb Company. To date, no patients have been exposed to IDX19368.

As part of the partial clinical hold placed on IDX184, the FDA has requested additional cardiac testing of patients in the ongoing phase IIb clinical trial of IDX184. More than 50 patients have been scheduled for echocardiograms, and the Company is on track to submit these data to the FDA in the coming weeks.

To date, echocardiograms have been performed on a small number of these patients, and the results are normal.

Idenix said that its primary concern is patient safety and it will work diligently to expedite this review process and continue its discussions with the FDA with the goal of further advancing its drug candidates, IDX184 and IDX19368, in clinical development.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Lowe's Companies, Inc. (LOW) reported second-quarter net earnings of $1.4 billion or $1.68 per share compared to $1.2 billion or $1.31 per share, a year ago. The second quarter results included a $96 million gain from the sale of the company's interest in its Australian joint venture. Excluding the gain,... Wal-Mart has applied for a U.S. patent for a blimp-style floating warehouse that could make deliveries through drones, Bloomberg reported. The world's largest retailer expects the proposed floating warehouse could help it lower the costs of fulfilling online orders, especially the expensive last-mile deliveries.. Shares of WPP Group Plc. were losing around 11 percent in the early morning trading in London after the advertising giant reported Wednesday that it has revised down fiscal 2017 forecast, despite reporting significant growth in first-half profit and revenues. The company attributed the revision to the pressure on client spending.
comments powered by Disqus
Follow RTT